Interferons (IFNs) are attractive biological response modifiers for use as therapeutic agents in infectious diseases, because they have both antiviral and immunomodulatory activity. Their name even comes from the fact that they can “interfere” with viral replication. IFN-α ("leukocyte interferon") and IFN-β ("fibroblast interferon") are released by human cells infected with certain viruses, whereas IFN-γ ("immune interferon") is produced by natural killer (NK) cells (T-cell lymphocytes) in response to antigen exposure. These cytokines then act on uninfected host tissue cells to induce a state of relative resistance to viral infections. The agents bind to specific cell-surface receptors that initiate a series of intracellular events: induction of certain enzymes, inhibition of cell proliferation, and enhancement of immune activities, including increased phagocytosis by macrophages and augmentation of specific cytotoxicity by T lymphocytes. Further details on endogenous IFN action and an explanation of their activity as biological response modifiers, including in bacterial infections, can be found elsewhere in this issue.

Even though IFNs’ role against viruses is most prominent, they can also be induced by, and active against, rickettsia, mycobacteria, and several protozoa. Therapeutically, however, their use has generally been limited to treatment or prevention of viral infections. Although their potent antiviral activity is promising—inhibiting viral replication and enhancing the antiviral effects of antiviral agents—it remains to be seen whether these effects will be sufficient to improve clinical outcomes in specific viral infections.
replication in vitro at concentrations as low as pg/mL—the development of IFNs as clinically useful drugs has been largely disappointing. This fact can be attributed partly to their short half-life in vivo and their extensive side effects. In fact, many symptoms of viral infections such as influenza can be blamed on endogenous IFN release. The adverse effects prevalent at therapeutic doses include fever, myalgia, and headache, dubbed “flu-like symptoms,” along with bone marrow suppression leading to leukocytopenia and thrombocytopenia, plus central nervous system manifestations including depression.1

IFNs have been studied for the treatment or prevention of herpes zoster, herpes simplex, and cytomegalovirus infections, but the successful development of acyclovir and ganciclovir gave clinicians safer and more effective alternatives for dealing with these viruses.5,6 IFNs can also be used in the treatment of multiple sclerosis and certain cancers, but this article reviews the therapeutic applications of IFNs for infectious diseases, focusing on viral infections.

INTERFERONS AND INTERFERON INDUCERS AVAILABLE COMMERCIVALLY

IFNs are not absorbed orally because of their large amino acid sequence, which is susceptible to the proteolytic enzymes in the digestive tract. However, IFN-α is readily absorbed after both intramuscular and subcutaneous injection.7 This rapid absorption combined with a short half-life means that frequent injections are needed to maintain adequate concentrations in the body. Both commercially available IFN-α products in the United States have now been chemically attached to polyethylene glycol (PEG) to enhance their half-life and make once-weekly dosing possible. This coupling not only makes administration easier, but also reduces side effects by having a predictably lower peak concentration of the exogenous cytokine.

Both pegylated INF-α2a (Pegasys) and IFN-α2b (Peg-Intron) are obtained from Escherichia coli by recombinant methods. These agents consist of naturally occurring small proteins with molecular weights of 15,000 to 27,600 Da.3 Each is considered a first-line option for the treatment of chronic hepatitis C virus (HCV) infection in combination with ribavirin. More details on this use and others are described later in this article. Along with the list of additional indications approved by the Food and Drug Administration shown in Table 1, IFN-α was shown to be an effective treatment for the symptoms of an aggressive case of chronic active Epstein-Barr virus, but did not eliminate infection entirely.8 Therefore, additional studies would need to be performed before recommendation for this use.

Human leukocyte derived IFN-αn3 (Alferon N) injection contains a spectrum of α IFNs, and is only approved for the treatment of refractory or recurring condylomata acuminata in adult patients. A low-dose oral version is in development for use in the treatment and prevention of influenza.9 Both versions have been studied against human immunodeficiency virus (HIV)-1 infection, but with little success.10,11 IFN alfacon-1 (Infergen) is considered the synthetic “consensus interferon” because it contains a nonnatural sequence of IFN-α amino acids all chosen for the highest activity against viral hepatitis. To date, no pegylated formulation of this product has been brought to market. All the α IFNs include a black-box warning in their prescribing information about how their use

…may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs and symptoms related to side effects. In many, but not all cases, these resolve after stopping therapy.12,13
| Product | Brand Name | FDA-Approved Indications | Usual Doses in Adults for Treatment of Indicated Infections |
|---------|------------|--------------------------|------------------------------------------------------------|
| Interferon-α2a & Peginterferon-α2a injection | Roferon-A, Pegasys | Chronic HCV, hairy cell leukemia and AIDS-related Kaposi sarcoma, Chronic HBV, HCV | 3 million units SC 3 times/wk 180 µg SC every wk × 24 or 48 wk |
| Interferon-α2b & Peginterferon-α2b injection | Intron A, Peg-Intron, Sylatron | Chronic HBV, chronic HCV, condylomata acuminata, hairy cell leukemia, follicular lymphoma, and AIDS-related Kaposi sarcoma, Chronic HCV, melanoma | 3 million units SC 3 times/wk 1.5 µg/kg SC every wk × 24 or 48 wk |
| Interferon alfacon injection | Infergen | Chronic HCV | 15 µg SC daily with ribavirin for retreatment of IFN refractory disease |
| Interferon-αn3 injection | Alferon N | Refractory or recurring external condylomata acuminata | Intralesional injection of 250,000 IU (0.05 mL) per wart twice weekly for up to 8 wk |
| Interferon-β1a injection | Avonex, Rebif | Relapsing multiple sclerosis | Not indicated for infection |
| Interferon-β1b injection | Betaseron | Relapsing multiple sclerosis | Not indicated for infection |
| Interferon-γ1b injection | ACTIMMUNE | Reduction in the frequency and severity of serious infections associated with CGD or treatment of severe, malignant osteopetrosis | 50 µg/m² (1 million IU/m²) for patients whose BSA is greater than 0.5 m² SC 3 times/wk |
| Imiquimod 5% topical cream | Aldara | Actinic keratoses of the face or scalp, superficial basal cell carcinoma, external genital and perianal warts/condyloma acuminata | Apply topically 3 times/wk until total clearance of warts or a maximum of 16 wk |
| Imiquimod 3.75% cream | Zyclara | Actinic keratoses of the full face or balding scalp, external genital and perianal warts/condyloma acuminata | Apply once daily to the warts until total clearance or up to 8 wk |

Abbreviations: AIDS, acquired immunodeficiency syndrome; BSA, body surface area; CGD, chronic granulomatous disease; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; IU, international units; SC, subcutaneously.
IFN-β1a (Avonex or Rebif) and IFN-β1b (Betaseron) are recombinant proteins with 166 and 165 amino acids, respectively. These β IFNs have antiviral and immunomodulatory properties too, but their use at this time is limited to treatment of multiple sclerosis, not infections. IFN-γ1b (ACTIMMUNE) injection is used regularly for the prevention of infections in patients with chronic granulomatous disease along with antibacterials and antifungals. Its mechanism of action for this purpose is not entirely known, but long-term studies show a definite benefit. IFN-γ can also be used as a salvage therapy for mycobacterial infections, but is not routinely used for treatment of this or other infections.

Topical imiquimod 5% (Aldara) and 3.75% (Zyclara) creams do not have inherent antiviral activity alone, but instead induce IFN-α, IFN-β, and IFN-γ plus tumor necrosis factor (TNF)-α through Toll-like receptors (TLRs). Local application to external genital and perianal warts results in an immunomodulatory response that stimulates cytokines, which have antiviral action and cause a reduction in both viral load and wart size.

USE OF INTERFERONS FOR HEPATITIS VIRUSES

Chronic infection with hepatitis B virus (HBV) and HCV affects over 400 million people worldwide. Chronic viral hepatitis is a leading cause of cirrhosis, liver transplantation, and hepatocellular carcinoma. With the development of a vaccination series for hepatitis B in the mid-1980s, along with increased public education and awareness, acute infection rates of both HBV and HCV in the United States have declined steadily.

HBV is a double-stranded DNA virus whereas HCV is a single-stranded RNA virus, both of which are capable of significant morbidity and mortality in chronic infection. The exact mechanisms of hepatic injury from HBV and HCV infection are not completely understood. Because asymptomatic carriers with normal liver transaminases exist, it is likely multiple immune-mediated mechanisms result in hepatocyte damage as opposed to the virus itself being directly cytotoxic.

Following acute viral infection, the innate immune response initiates formation of NK cells, followed by virus-specific CD4+ T cells and CD8+ cytotoxic T lymphocytes. NK cells stimulate production of IFN-α/β and promote cellular clearance of viral proteins through disruption of the replication process. Following successful clearance, either spontaneously or by treatment with IFN, peripheral cytotoxic T lymphocytes and CD4+ T-cell response persists. Chronic infection is likely a result of failed innate and adaptive immunity. Specifically, chronic infection with HCV has been associated with impaired T-cell and NK-cell response. Genetic factors also likely influence progression of disease and predisposition to adverse effects. Although an abundance of research has investigated the immune response in relation to chronic viral hepatitis, many areas of uncertainty still exist.

Standard IFN-α, the first approved IFN for viral hepatitis, lacked several desirable pharmacokinetic properties. The addition of PEG created an IFN that has a slower rate of absorption, reduced elimination, and a longer half-life, necessitating less frequent dosing and fewer adverse effects. Furthermore, the PEG moiety results in reduced immunogenicity and sterically hinders the antigenic binding site. Although pegylated IFN has replaced standard IFN-α in treatment of chronic HBV and HCV, as many as 40% to 50% of patients still fail to respond to treatment. Successful response depends on many factors including but not limited to viral genotype, viral load, and degree of liver fibrosis.

Chronic hepatitis B and C are treated similarly with peginterferon (pegIFN); however, only pegIFN-α2a is FDA-approved in the United States for treatment of HBV. Both
PegIFN products are administered as subcutaneous injections once weekly for durations up to 48 weeks, dependent on viral genotype and early viral response for treatment of HCV. PegIFN-α2b is dosed based on body weight (1.5 μg/kg once weekly) whereas pegIFN-α2a is a fixed dose (180 μg/wk). Ribavirin is used in combination with pegIFN for treatment of HCV. The exact mechanism of action of ribavirin as an adjunctive antiviral agent in HCV is not completely understood. Some studies have proposed ribavirin to act as an IFN-stimulated gene inducer to improve second-phase viral decline. Protease inhibitors (boceprevir and telaprevir) are recently approved adjunctive oral agents for the treatment of chronic HCV with pegIFN and ribavirin. To date, all studies of protease inhibitors have been conducted in patients with HCV genotype 1, and have shown an increase in sustained virologic response (SVR) rates particularly for patients previously unresponsive to IFN therapy.

The use of IFN for the treatment of chronic HBV and HCV has represented a mainstay of treatment for several decades. The specific mechanisms behind the antiviral effects of IFN for hepatitis are complex. IFN-stimulated genes are induced by IFN and disrupt viral replication. Hundreds of IFN-stimulated genes are thought to exist. Viperin, ISG20 and protein kinase R (PKR) are just a few of the most commonly cited. It is also highly possible that IFN-stimulated genes work synergistically to produce antiviral activities. A lack of PKR can lead to an environment conducive to HCV replication, though it may not be a good predictor of exogenous IFN response. The study of IFN-stimulated genes and their role in determining who responds to IFN therapy has been evaluated in several studies. Additional studies of IFN-stimulated gene expression are needed to clarify which are directly involved in successful viral response, in what capacity they affect response, and whether pharmacotherapy directed at induction of IFN-stimulated genes can help improve treatment response.

**Hepatitis B**

Chronic HBV infection can be successfully treated with IFN monotherapy. Loss of viral DNA and antibody formation are successful outcomes associated with IFN treatment. The mechanism of IFN antiviral activity varies depending on hepatitis Be antigen (HBeAg)-positive or HBeAg-negative disease. In HBeAg-positive patients, an immune response is stimulated by IFN whereas in HBeAg-negative disease, IFN acts directly as an antiviral. HBeAg-negative disease tends to be more difficult to treat, and is associated with a longer duration of disease and a higher likelihood of complications such as cirrhosis. Several oral nonnucleoside reverse transcriptase inhibitors are also available for treatment of HBV (entecavir, tenofovir, adefovir, lamivudine, and telbivudine). Although IFN is still considered a first-line alternative and provides the advantage of defined treatment duration rather than potentially lifelong administration, these oral agents are often used in therapy because of their ease of use and reduced number of side effects associated with treatment.

**Hepatitis C**

The ability of HCV to evade the host immune response has produced a complex RNA virus capable of lingering infection, ultimately resulting in opportunities for increased risk of transmission and complications from advanced liver disease. Much of the research regarding the use of IFN for chronic viral hepatitis has focused on use in HCV. Following treatment with IFN, a decline in HCV RNA occurs over several phases. A rapid inhibition of RNA production within the first 1 to 2 days of treatment is followed by a second, slower phase associated with clearance of infected cells.
immune response to endogenous IFN produced by innate immunity and that administered exogenously can differ in terms of antiviral activities based on the phase of viral decline.

Studies have shown that response to IFN-based treatment for HCV may be affected by differences in IFN signaling and induction. It is likely that HCV has mechanisms to avoid recognition by the innate immune response, and as such inhibits the ability of HCV-infected cells to generate IFN.25,38,42 Early studies conducted in nonresponders to current therapy showed wide genetic diversity, with many showing no common traits to predict nonresponse to IFN therapy.25,38,43

However, in 2009 several major studies were published associating a single-nucleotide polymorphism (SNP) just upstream from interleukin-28B gene (IL28B) with IFN response in patients with HCV genotype 1.44–48 Additional evidence points to the fact that the IL28B polymorphism is also linked to spontaneous clearance of HCV.48,49 The IL28B variant encodes for IFN-λ3, a type III IFN belonging to the interleukin (IL)-10 superfamily, which function in a manner similar to type I IFNs, resulting in IFN-stimulated gene induction.49–51

The genome-wide association study conducted by Ge and colleagues45 evaluated more than 1600 treatment-naïve HCV genotype 1 patients, the majority of whom originated from the IDEAL study. Results from logistic regression showed that the IL28B polymorphism was a stronger predictor of SVR than baseline viral load, ethnicity, or degree of fibrosis. Further research in this area is needed to clearly identify a future role for genotype testing and further clarify whether it may influence response to therapy in other HCV genotypes.

A multicenter, randomized, controlled study by Mangia and colleagues52 analyzed 268 Caucasian patients with HCV genotype 2 (n = 213) and 3 (n = 55). Out of 61% of patients who achieved rapid virologic response (RVR), IL28B genotype was not associated with SVR, whereas in those patients who did not achieve RVR a significant difference in SVR was noted based on IL28B genotype. At this time genotype testing for IL28B is not routinely recommended for all HCV patients planning to undergo treatment, but it may be in the future. If done, it should not be used as the only factor when choosing a treatment strategy.49

Investigational IFN Therapies

The complexity of viral defense mechanisms and subsequent effect on the host response has led not only to development of chronic infections but also to a lack of a viable vaccine. HCV viral polymerase lacks a proofreading capability, creating a more diverse target for vaccine development.18 Additional challenges include the lack of a suitable animal model to mimic a human environment and medium for viral growth.18

One of the major limitations to IFN therapy is adverse effects. Malaise, gastrointestinal effects, neuropsychiatric effects, neutropenia, and anemia can all limit the effectiveness of treatment by necessitating dosage reductions or treatment discontinuation. For newer IFN therapies to be successful, they must induce an antiviral response while at the same time limiting adverse effects.

Albinterferon is a new IFN therapy currently in development for the treatment of chronic HCV. This product is a combination of IFN-α2b fused to recombinant human albumin. One of the advantages with this product is that it only requires once or twice monthly dosing.53 Not much is known at this time about the immunomodulating effects of albinterferon in HCV. It has been shown to have similar SVR and adverse event rates to traditional pegIFN when used in combination with ribavirin.54–56
Research into IFN-λ as an agent to treat HCV has also been initiated. It is hypothesized that λ IFNs may be associated with less adverse effects than IFN-α because IFN-λ receptors are primarily found in hepatocytes. Specifically, research into new investigational pharmacotherapy in the form of pegylated IL-29 (IFN-λ1) in patients with HCV genotype 1 who relapsed following traditional treatment with peg-IFN-α and ribavirin appears promising. Both IFN-λ1 and IFN-λ3 share a common receptor and have a similar sequence identity.

A 4-week, open-label study conducted in 56 patients with chronic HCV genotype 1 was designed to assess pegIFN-λ1 in combination with ribavirin. It was a dose escalation study conducted in 3 parts. Parts 1 and 2 evaluated patients who relapsed following treatment with IFN-α, and part 3 included treatment-naïve patients. In part 1, pegIFN-λ monotherapy (1.5 μg/kg or 3 μg/kg) was administered subcutaneously every 2 weeks or weekly. In parts 2 and 3, a range of pegIFN-λ dosages (0.5 μg/kg, 0.75 μg/kg, 1.5 μg/kg, or 2.25 μg/kg) were administered weekly in combination with ribavirin twice daily (1000 mg if weight <75 kg and 1200 mg if weight ≥75 kg). The primary outcomes were safety and tolerability. Pharmacokinetics and viral load reduction were evaluated as secondary end points.

Commonly reported adverse effects with pegIFN-λ included fatigue (29%), nausea (12%), myalgia (11%), and headache (9%). Most adverse events were mild or moderate in severity. Four patients (7%) experienced treatment-related toxicity and required doses to be withheld. One patient experienced grade 3 thrombocytopenic purpura and another patient had elevated alanine aminotransferase, aspartate aminotransferase, and bilirubin levels. Both events were considered to be related to treatment with pegIFN-λ. Aminotransferase elevations occurred most often in patients who received high-dose (3 μg/kg) pegIFN-λ monotherapy. No clinically relevant decreases in absolute neutrophil count occurred. Also, hemoglobin values remained consistent with known effects in patients who received ribavirin therapy. Viral activity decreased in the majority of patients who relapsed with previous treatment, with 23 of 24 patients achieving at least a greater than 2-log reduction in HCV RNA. Six of 7 treatment-naïve patients achieved a similar reduction in viral load and 2 achieved undetectable HCV RNA levels. Kinetic data showed a linear relationship between dose and exposure independent of body weight, which may prompt future research to evaluate a fixed dose of pegIFN-λ.

Larger, longer, controlled, and blinded studies of IFN-λ as a viable treatment option in HCV are needed to define its place in therapy and benefits over existing IFN therapy. Studies in other HCV genotypes are also needed. In addition, with the advent of protease inhibitors, more research will be necessary to evaluate how direct antivirals and IL28B genotyping interact in guiding treatment decisions.

Adjunctive therapy with agents that induce or restore IFN-stimulated gene expression has recently been evaluated in patients with HCV. S-Adenosylmethionine (SAMe) given orally was evaluated in an open-label study in 24 patients with chronic HCV, genotype 1 who were considered nonresponders to previous IFN and ribavirin treatment. SAMe was administered at a dose of 800 mg twice daily in combination with pegIFN-α2a (180 μg/kg weekly) and weight-based ribavirin (1000 mg if weight <75 kg and 1200 mg if weight ≥75 kg). The primary outcome was change in first-phase and second-phase viral decline. Treatment response and IFN-stimulated gene expression were also evaluated after up to 72 weeks of treatment. Results showed significant improvement in second-phase viral decline assessed at 2 weeks. SVR was also evaluated; however, this study was not powered to detect differences in virologic response rates. Furthermore, at the time of publication not all patients had reached 24 weeks post treatment, so the full effects on SVR were not fully known.
The addition of SAMe showed greater induction of IFN-stimulated genes, including viperin, myxovirus resistance protein, and ISG15, compared with control. Adverse effects noted with SAMe were mild and mostly related to gastrointestinal upset, likely as a result of lactose in the tablet preparation. Additional research is aimed at investigating structure-activity relationships, and preliminary pharmacokinetic studies on oral IFN inducers that act on TLRs in the treatment of HCV.

**USE OF INTERFERONS FOR RESPIRATORY VIRUS INFECTION**

Upper respiratory tract infection in the form of “the common cold” can be caused by a variety of viruses including rhinovirus, coronavirus, influenza, parainfluenza, respiratory syncytial virus, adenovirus, Coxsackie, and echovirus families among others. Symptoms may include rhinorrhea, nasal obstruction, cough, fever, and sore throat. The disease is usually mild and self-limited, but several trials have addressed treatment or prevention of the common cold with therapeutic agents. IFNs were once one of the most popular prospects for this purpose, but the minor benefit that was derived from them was counteracted by the adverse effects inflicted.

An early double-blind trial with IFN-α2b intranasal drops did demonstrate that with use for several days before experimentally induced rhinovirus infection, common cold symptoms were significantly fewer in study participants compared with placebo-drop users. Administration of the drops 4 times daily was superior to a higher dose given once daily at preventing infection. Short-term use was well tolerated, but obviously it is not realistic for everyone to use intranasal drops 4 times daily throughout the entire cold season. In an attempt to prevent natural infection during the period of increased acute respiratory tract virus activity, a twice-daily nasal spray was studied in volunteers over 28 days. There was a significant decrease in the number of rhinovirus infections noted, but not in any other types of viral respiratory tract infections including parainfluenza. Adverse events with the IFN formulation were common in this placebo-controlled trial. During the first week alone, 20% of participants receiving IFN spray reported nosebleeds. This number increased to 41% by the end of the study.

Providing IFN prophylaxis for family members of those infected with common cold viruses is a more targeted approach to therapy. Several studies have addressed the usefulness of IFN nasal sprays in this scenario. Seven days of use did significantly reduce rhinovirus infections in 2 different trials when compared with placebo for both individuals (7.9% vs 15.5%) and their families (3.3% vs 33.3%, both P<.05), but not in 2 other studies when lower doses were given for a shorter 5-day course. Overall, the intranasal dose of IFN needed to protect against upper respiratory tract infection appears to cause significant unwanted effects. Infection with coronavirus and respiratory syncytial virus has also been an object of investigation for IFN-α2b nasal sprays, but with little success. A study of intranasal human lymphoblastoid IFN-αn1 (Wellferon) suggested lower prophylactic activity for influenza than it did for rhinovirus.

Because results of prophylactic trials with IFNs for common cold viruses were not favorable, use in the treatment of infection seemed a logical application for this biological response modifier. Although some benefit was originally seen with twice-daily IFN-α2b intranasal drops for treatment of experimentally induced rhinovirus, no advantage was clear when an intranasal spray was used once daily for 5 days to treat natural infection. Increased rates of blood in the mucus were again noted for participants receiving the intervention, and the IFN group experienced more secondary complications requiring prescription of antibiotics. The investigators concluded that
intranasal IFN was ineffective for treating the common cold and was associated with clinically significant side effects.

Similar trials with IFN-β-serine and IFN-γ formulations, although initially positive, have shown equally disappointing clinical results. Even though the prospects of further study on IFNs for upper respiratory tract infection appear limited, one modern trial did demonstrate an added benefit of intranasal IFN-α2b in combination with an antihistamine (chlorpheniramine) and nonsteroidal anti-inflammatory drug (ibuprofen) at reducing common cold symptoms, showing that at least one group is still interested in studying the topic.Investigators have also recently begun research on an alternative therapeutic approach for rhinovirus infections using the IFN and TNF-α inducer, imiquimod. Application of this intranasal cream in primates has shown promising results in terms of enhancing cytokine response, but human trials have not yet been published.

USE OF INTERFERONS FOR GENITAL INFECTIONS AND WARTS

Human papillomaviruses (HPVs) are now known to be the cause of cervical cancer and are also responsible for genital warts. HPVs are nonenveloped, double-stranded DNA viruses that invade mucosal and epithelial tissues during sexual contact with an infected partner. It is estimated that more than 50% of the sexually active American population has been or will be infected with HPV at one point in their lives. When hyperproliferation of infected cells occurs, this can lead to genital warts or cancer of the cervix, vagina, vulva, and penis, among others. There are more than 100 different types of HPV and approximately 40 of them infect genital mucosa. Fifteen carcinogenic types of HPV have been identified, but 2 of them are associated with 70% of cervical cancers. Two vaccines have recently been introduced that prevent infection with these most common high-risk types of HPV, 16 and 18. One of these vaccines can also induce protection against the most prevalent HPV types that have a low risk of malignancy, but instead cause genital warts: HPV-6 and HPV-11.

HPV has the ability to persist in stratified epithelia for decades because of mechanisms that avoid immune eradication. IFN plays a large role in this cycle. IFNs are normally secreted by keratinocytes, but HPV reduces their expression. Introduction of low-level IFN can actually increase early gene transcription and HPV replication, which may explain why use of the agent therapeutically has had mixed results. Overall outcomes have been positive more often for cases of genital warts than reduction of HPV lesions associated with cancers. A study comparing the in vitro activity of IFN-α2b and IFN-αn3 on oncogenic HPV-16, HPV-18, and HPV-31b demonstrated that increasing concentrations did not always correlate with a stepwise inhibition of HPV replication. Meanwhile, a meta-analysis recently analyzed locally used and systemic IFN for genital warts. Seven randomized studies of IFN intralesional injection or topical gel met criteria for inclusion, and overall there was a benefit in complete response rates over placebo (44.4% vs 16.15%, relative risk 2.68, 95% confidence interval 1.79–4.02). However, there was no difference in outcomes for trials comparing systemic IFNs with placebo. In comparison, clearance of genital and perianal warts occurs in 50% of patients with the topical IFN inducer imiquimod, usually after 8 to 10 weeks of use. The 5% imiquimod cream (Aldara) should be applied to affected areas 3 times a week for up to 16 weeks, whereas the newer 3.75% cream (Zyclara) can be applied once daily for as little as 8 weeks to treat external genital warts caused by HPV.

Systemic IFN therapy may be useful when HPV affects areas of the body other than the anogenital region. Successful treatment with systemic pegIFN-α and a topical...
retinoid has been reported for mucosal carcinomas from epidermodysplasia verruciformis, a genetic abnormality leading to persistent and widespread HPV infection of the skin. Recurrent respiratory HPV infection has also been effectively treated with IFN-α (12 of 18 patients), although it had no effect on viral load or replication. A 20-year follow-up of patients treated with IFN-α for recurrent respiratory papillomatosi s confirmed better response rates for HPV-6 than HPV-11, which had a higher likelihood of malignant transformation. For recurrent conjunctival papilloma, topical plus systemic or intralesional IFN has been effective with partial excision. The rapid resolution of significant HPV-associated warts on the hand, foot, and face has also occurred in an HIV-infected patient on antiretrovirals while being treated for hepatitis C with pegIFN-α2b and ribavirin.

Case reports of treatment with the topical IFN inducer, imiquimod, have shown promise for its use in focal epithelial hyperplasia (Heck disease), a rare disorder caused by specific types of HPV (13, 14, 32, and 55) affecting oral mucosa primarily in children. In addition, imiquimod 5% cream has been used successfully in the treatment of planter warts, a smoother, flatter manifestation of HPV-1, HPV-2, and HPV-4 on the foot. Of interest, the oral H2-antagonist cimetidine, along with reducing stomach acid, also induces production of IFN-γ and IL-2, which eliminates viral warts in some patients. In the future the improved application of more effective topical IFNs may become a reality, which could provide a valuable treatment for HPV infections without the systemic side effects of current injectable formulations.

USE OF INTERFERONS AS VACCINE ADJUVANTS

Adjuvants (adjuvare, Latin for “to help”) are substances that augment the immunogenicity of an antigen when mixed with the antigen for use in a vaccine. Adjuvants (1) stimulate granuloma (which is a macrophage-rich mass), (2) enhance costimulatory signals, (3) stimulate nonspecific lymphocyte production, (4) prolong the antigen concentration in a site for lymphocyte exposure, and (5) induce cytokines. Research in vaccine development has shown that one of the most promising uses of IFNs is as an adjuvant with specific antigens in prophylactic vaccines. Toporovski and colleagues provide a current review of the use of IFN-α, IFN-β, IFN-γ, and IFN-λ in vaccine studies that focus primarily on murine, avian, porcine, and nonhuman species. Regardless of the species, the use of IFNs as adjuvants seems to improve the efficacy and safety of most vaccines while providing the immunomodulatory effect of stimulating the T-helper 1 response.

In humans, IFN-α, predominantly produced by plasmacytoid dendritic cells, plays a large role in the body’s immune response against viruses. It induces plasma cell differentiation from B cells causing an increase in the serum level of influenza-specific immunoglobulins, and channels antigen-presenting cells (APCs) to the site of infection. Most research on IFN-α adjuvant activity and its subsequent use in approved vaccines seems to indicate that it is a potent adjuvant. When mixed with the influenza vaccine and injected intramuscularly, it is a highly effective adjuvant. Oromucosal administration of recombinant IFN-α, like that of natural oromucosal IFN production, has been shown to provide immunity against viral infection and tumor cell growth. Nonresponders low responders to a previous vaccine showed an improved immunoglobulin response with a recombinant IFN-α and HBV vaccine.

Although research is also focused on the other classes of IFNs as adjuvants, thus far they have not yielded results as promising as that of IFN-α. The use of IFN-β has yielded mixed results; IFN-γ has been used primarily in DNA vaccines; and even less is known about the use of IFN-λ in vaccines. Nevertheless, the use of IFNs as
adjuvants shows great promise in augmenting vaccine efficiency, and should continue to be a top priority in the development of vaccines.

SUMMARY

IFNs have been tested repeatedly against infectious diseases, but injections are used mostly for the treatment of viral hepatitis C and prevention of infections in patients with chronic granulomatous disease clinically. Intralesional IFN and topical inducers are effective in reducing the manifestations of genital warts, but they do not eliminate cancer-causing HPV from the body. IFN has not proved to be consistently effective for treatment of respiratory tract infections from the common cold or influenza viruses, and prophylactic use is not currently feasible. The severity and quantity of adverse effects from systemic IFN therapy make it unattractive for many uses. Several infections, including herpes simplex, herpes zoster, cytomegalovirus, and even viral hepatitis B have other effective pharmacologic treatments. IFN has been successfully used as a vaccine adjuvant, and further research may allow for its additional use for this application in the future.

REFERENCES

1. Goering RV, Dockrell HM, Zuckerman M, et al. Mim’s medical microbiology. 4th edition. Philadelphia: Elsevier Limited; 2008.
2. Male D, Brostoff J, Roth D, et al. Immunology. 7th edition. Philadelphia: Elsevier Limited; 2006.
3. Hayden FG. Antiviral agents. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th edition. New York: McGraw-Hill; 2006. p. 1225–42.
4. Mullangi P, Shahani L, Koirala J. Role of endogenous biological response modifiers in pathogenesis of infectious diseases. Infect Dis Clin North Am, in press.
5. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6(12):975–90.
6. Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007;2:CD005129.
7. Houglum JE. Interferon: mechanisms of action and clinical value. Clin Pharm 1983;2(1):20–8.
8. Sakai Y, Ohga S, Tonegawa Y, et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: Potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998;20(4):342–6.
9. FDA authorizes Alferon LDO clinical study for treatment and prevention of influenza. Hemispherx Biopharma, Inc. Press Release. Available at: http://www.drugs.com/news/fda-authorizes-alferon-ldo-clinical-study-prevention-influenza-28692.html. Accessed April 25, 2011.
10. Alston B, Ellenberg JH, Standiford HC, et al. A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells/mm(3). Division of aids treatment research initiative (DATRI) 022 study group. J Acquir Immune Defic Syndr 1999;22(4):348–57.
11. Fitzgibbon JE, John JF. In vitro activity of interferon-alpha n3 (Alferon n) against HIV-1. Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract no: I-13] vol. 38. San Diego (CA): American Society of Microbiology; 1998. p. 367.
12. Hoffman-LaRoche Inc [package insert]. Nutley, NJ: Pegasys® (peg-interferon alfa-2a); 2010.
13. Schering Corporation [package insert]. Kenilworth, NJ: Peg-Intron® (peginterferon alfa-2b); 2010.
14. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324(8):509–16.
15. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39(5):692–9.
16. Rao S, Blessman D, Koirala J, et al. Biological response modifiers as adjunct treatment for refractory localized Mycobacterium avium complex infections. J Invest Med 2005;53(S2):S398.
17. Hepatitis B. Fact sheet: World Health Organization. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html. Accessed March 24, 2011.
18. Initiative for vaccine research. Viral cancers: World Health Organization. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html. Accessed April 6, 2011.
19. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ 2009;58(3):1–27.
20. Aoki FA, Hayden FG, Dolin R. Antiviral drugs (other than antiretrovirals). In: Mandell GL, Bennett JE, Dolin R, editors, Principles and practices of infectious diseases, vol. 1. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 565–610.
21. Crotta S, Ronconi V, Ullivieri C, et al. Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol 2006;36(4):919–29.
22. Golden-Mason L, Rosen HR. Natural killer cells: primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006;12(3):363–72.
23. Stegmann KA, Bjorkstrom NK, Veber H, et al. Interferon-alpha-induced trail on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010;138(5):1885–97.
24. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002;169(6):3447–58.
25. Wada M, Marusawa H, Yamada R, et al. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. J Viral Hepat 2009;16(6):388–96.
26. He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 1999;65(4):355–68.
27. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001;3(1):30–7.
28. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139(1):154–62 e4.
29. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207–17.
30. Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009;13(3):429–39.
31. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49(2):163–9.

32. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46(3):640–8.

33. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132(4):1270–8.

34. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827–38.

35. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360(18):1839–50.

36. Fitzgerald KA. The interferon inducible gene: Viperin. J Interferon Cytokine Res 2011;31(1):131–5.

37. Jiang D, Guo H, Xu C, et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008;82(4):1665–78.

38. Pfeffer LM, Madey MA, Riely CA, et al. The induction of type I interferon production in hepatitis C-infected patients. J Interferon Cytokine Res 2009;29(5):299–306.

39. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6(12):1315–41 [quiz: 286].

40. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37(6):1351–8.

41. Feld JJ, Modi AA, El-Diwany R, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology 2011;140(3):830–9.

42. Meurs EF, Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 2007;13(17):2446–54.

43. Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, et al. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One 2008;3(8):e3058.

44. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011;364(13):1272–4.

45. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28b predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399–401.

46. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28b is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41(10):1100–4.

47. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28b with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105–9.

48. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28b and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798–801.

49. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011;53(1):336–45.
50. Liapakis A, Jacobson I. Pharmacogenetics of hepatitis C therapy. Pharmacoge-
nomics 2010;11(2):135–9.
51. Shackel NA, Bowen DG, McCaughan GW. Snipping away at hepatitis C. Hepa-
tology 2010;51(2):703–5.
52. Mangia A, Thompson AJ, Santoro R, et al. An IL28b polymorphism determines
treatment response of hepatitis C virus genotype 2 or 3 patients who do not
achieve a rapid virologic response. Gastroenterology 2010;139(3):821–7, 27. e1.
53. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every
two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis
C. Hepatology 2008;48(2):407–17.
54. Bain VG, Kaita KD, Marotta P, et al. Safety and antiviral activity of albinterferon
alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.
Clin Gastroenterol Hepatol 2008;6(6):701–6.
55. Nelson DR, Benhamou Y, Chuang WL, et al. Albinterferon alfa-2b was not inferior
to pegylated interferon-alpha in a randomized trial of patients with chronic hepa-
titis C virus genotype 2 or 3. Gastroenterology 2010;139(4):1267–76.
56. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon alfa-2b was not inferior
to pegylated interferon-alpha in a randomized trial of patients with chronic hepa-
titis C virus genotype 1. Gastroenterology 2010;139(4):1257–66.
57. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon
lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis
C virus infection. Hepatology 2010;52(3):822–32.
58. Tran TD, Pryde DC, Jones P, et al. Design and optimisation of orally active TLR7
agonists for the treatment of hepatitis C virus infection. Bioorg Med Chem Lett
2011;21(8):2389–93.
59. Turner RB. The common cold. In: Mandell GL, Bennett JE, Dolin R, editors. Prin-
ciples and practices of infectious diseases. Philadelphia: Churchill Livingston
Elsevier; 2010. p. 803–13.
60. Enlow ML, Haley CJ. Alpha 2-interferon for the common cold. Ann Pharmacother
1992;26(3):345–7.
61. Hayden FG, Gwaltney JM Jr. Intranasal interferon alpha 2 for prevention of rhino-
virus infection and illness. J Infect Dis 1983;148(3):543–50.
62. Monto AS, Shopec TC, Schwartz SA, et al. Intranasal interferon-alpha 2b for
seasonal prophylaxis of respiratory infection. J Infect Dis 1986;154(1):128–33.
63. Douglas RM, Moore BW, Miles HB, et al. Prophylactic efficacy of intranasal
alpha 2-interferon against rhinovirus infections in the family setting. N Engl J
Med 1986;314(2):65–70.
64. Hayden FG, Albrecht JK, Kaiser DL, et al. Prevention of natural colds by con-
tact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986;314(2):
71–5.
65. Monto AS, Schwartz SA, Albrecht JK. Ineffectiveness of postexposure prophy-
laxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in fami-
lies. Antimicrob Agents Chemother 1989;33(3):387–90.
66. Herzog C, Berger R, Fernex M, et al. Intranasal interferon (rIFN-alpha a, Ro
22-8181) for contact prophylaxis against common cold: a randomized, double-
blind and placebo-controlled field study. Antiviral Res 1986;6(3):171–6.
67. Scott GM, Onwubalili JK, Robinson JA, et al. Tolerance of one-month intranasal
interferon. J Med Virol 1985;17(2):99–106.
68. Turner RB, Felton A, Kosak K, et al. Prevention of experimental coronavirus
colds with intranasal alpha-2b interferon. J Infect Dis 1986;154(3):443–7.
69. Higgins PG, Barrow GI, Tyrrell DA, et al. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 1990;14(1):3–10.

70. Phillipotts RJ, Higgins PG, Willman JS, et al. Intranasal lymphoblastoid interferon (“Wellferon”) prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984;4(4):535–41.

71. Hayden FG, Gwaltney JM Jr. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis 1984;150(2):174–80.

72. Hayden FG, Kaiser DL, Albrecht JK. Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother 1988;32(2):224–30.

73. Sperber SJ, Levine PA, Innes DJ, et al. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. J Infect Dis 1988;158(1):166–75.

74. Sperber SJ, Levine PA, Sorrentino JV, et al. Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds. J Infect Dis 1989;160(4):700–5.

75. Higgins PG, Al-Nakib W, Willman J, et al. Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res 1986;6(2):153–9.

76. Higgins PG, Al-Nakib W, Barrow GI, et al. Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers. J Interferon Res 1988;8(5):591–6.

77. Gwaltney JM Jr, Winther B, Patrie JT, et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis 2002;186(2):147–54.

78. Clejan S, Mandrea E, Pandrea IV, et al. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J Cell Mol Med 2005;9(2):457–61.

79. Genital HPV infection—fact sheet. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed April 25, 2011.

80. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518–27.

81. Bergman SJ, Collins-Lucey E. Update on human papillomavirus vaccines: life saver or controversy magnet? Clin Microbiol Newslett, in press.

82. Beglin M, Melar-New M, Laimins L. Human papillomaviruses and the interferon response. J Interferon Cytokine Res 2009;29(9):629–35.

83. Lace MJ, Anson JR, Klingelhutz AJ, et al. Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis 2009;30(8):1336–44.

84. Sen E, McLaughlin-Drubin M, Meyers C. Efficacy of two commercial preparations of interferon-alpha on human papillomavirus replication. Anticancer Res 2005;25(2A):1091–100.

85. Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis 2009;9(1):156.

86. Shrestha NK, Hamrock DJ. Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin. Clin Infect Dis 2010;51(1):e4–6.
87. Gubinelli E, Posteraro P, Cocuroccia B, et al. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog Treat 2003;14(3):184–8.
88. Szeps M, Dahlgren L, Aaltonen LM, et al. Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment. J Gen Virol 2005;86(Pt 6):1695–702.
89. Gerein V, Rastorguev E, Gerein J, et al. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114(6):463–71.
90. de Keizer RJ, de Wolff-Rouendaal D. Topical alpha-interferon in recurrent conjunctival papilloma. Acta Ophthalmol Scand 2003;81(2):193–6.
91. Kothari M, Mody K, Chatterjee D. Resolution of recurrent conjunctival papilloma after topical and intralesional interferon alpha2b with partial excision in a child. J AAPOS 2009;13(5):523–5.
92. Pavan MH, Velho PE, Vigani AG, et al. Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin. Braz J Infect Dis 2007;11(3):383–4.
93. Yasar S, Mansur AT, Serdar ZA, et al. Treatment of focal epithelial hyperplasia with topical imiquimod: report of three cases. Pediatr Dermatol 2009;26(4):465–8.
94. Zamiri M, Gupta G. Plantar warts treated with an immune response modifier: a report of two cases. Clin Exp Dermatol 2003;28(Suppl 1):45–7.
95. Mitsuishi T, Iida K, Kawana S. Cimetidine treatment for viral warts enhances IL-2 and IFN-gamma expression but not IL-18 expression in lesional skin. Eur J Dermatol 2003;13(5):445–8.
96. Foldvari M, Badea I, Kumar P, et al. Topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections. Curr Drug Deliv 2011;8(3):307–19.
97. Kuby J. Immunology. New York: W.H. Freeman and Co; 1997.
98. Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17(11):1075–81.
99. Toporovski R, Morrow MP, Weiner DB. Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther 2010;10(10):1489–500.
100. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003;19(2):225–34.
101. Tovey MG, Lallemand C, Meritet JF, et al. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006;24(Suppl 2):46–7.
102. Tovey MG, Maury C. Oromucosal interferon therapy: marked antiviral and anti-tumor activity. J Interferon Cytokine Res 1999;19(2):145–55.
103. Goldwater PN. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hypo-responders. Vaccine 1994;12(5):410–4.